Overexpression of kallikrein 10 in epithelial ovarian carcinomas.

OBJECTIVE We wanted to identify genes up-regulated in ovarian tumors that might serve as early markers for ovarian cancer. One promising focus is the family of genes that encode secreted proteases, which play essential roles in tumor invasion and metastasis. Kallikrein 10 (KLK10) is a member of the kallikrein family of serine proteases which include 15 proteins, including the prostate-specific antigen (PSA), also known as hK3. We investigated whether KLK10 and its related protein, hK10, might serve as equally accurate markers for ovarian carcinoma. METHODS Transcriptional profiling was performed using RNA isolated from normal ovarian epithelium, ovarian cancer cell lines, and primary ovarian tumors. Microarray data were confirmed by Northern blot analysis of 66 ovarian tumor samples and 6 ovarian cancer cell lines. In situ hybridization and Western blot analysis confirmed the Northern blot findings. RESULTS KLK10 was more highly expressed by primary ovarian tumors than by NOE. Thirty-two of 35 primary serous ovarian carcinoma samples (91.4%) expressed higher levels of KLK10 than NOE did. Eleven of 15 nonserous epithelial ovarian carcinoma samples (73.3%) and 8 of 11 primary peritoneal carcinoma samples (72.7%) also expressed KLK10. Overall, 84.8% of all epithelial ovarian and peritoneal carcinoma tumor samples showed elevated expression of KLK10. Similarly, Western blot analysis demonstrated that levels of the KLK10-related protein, designated hK10, are elevated in primary ovarian tissue lysates, but the protein is undetectable in immortalized ovarian epithelium. Finally, in situ hybridization established that KLK10 mRNA is much more highly expressed by tumor tissue than by normal epithelium and stromal tissues. CONCLUSIONS Our data support recent immunoassay findings of elevated levels of hK10 in the tumor tissue and serum of ovarian cancer patients. Thus, it is likely that KLK10 and other kallikreins will serve as useful diagnostic and prognostic markers in patients with ovarian carcinoma.

[1]  D. Katsaros,et al.  Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  R. Moll,et al.  Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary. , 1985, European journal of cell biology.

[3]  S. Naber,et al.  Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[5]  E. Diamandis,et al.  Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. , 2001, Clinical chemistry.

[6]  David I. Smith.  Transcriptional profiling develops molecular signatures for ovarian tumors. , 2002, Cytometry.

[7]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[8]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Katsaros,et al.  Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. , 2001, Cancer research.

[10]  J. Lautenberger,et al.  Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells , 1982, Nature.

[11]  M. Bittner,et al.  Expression profiling using cDNA microarrays , 1999, Nature Genetics.

[12]  A. Ashworth,et al.  Microarray and histopathological analysis of tumours: the future and the past? , 2001, Nature Reviews Cancer.

[13]  N. Auersperg,et al.  Serial propagation of human ovarian surface epithelium in tissue culture , 1988, Journal of cellular physiology.

[14]  P. Kruk,et al.  Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[15]  L. Hood,et al.  Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.

[16]  E. Diamandis,et al.  The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. , 2000, Anticancer research.

[17]  D. Katsaros,et al.  Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  D. Wazer,et al.  The role for NES1 serine protease as a novel tumor suppressor. , 1998, Cancer research.

[19]  Eleftherios P. Diamandis,et al.  The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.

[20]  G. Yousef,et al.  The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.

[21]  Terukazu Nakamura,et al.  Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. , 2002, Cancer research.

[22]  D. Katsaros,et al.  Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. , 2001, Cancer research.

[23]  D. Wazer,et al.  Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. , 1996, Cancer research.

[24]  P. Kruk,et al.  Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. , 1992, American journal of obstetrics and gynecology.

[25]  N. Hacker,et al.  Current management of epithelial ovarian carcinoma: a review. , 2000, Seminars in surgical oncology.

[26]  D. Katsaros,et al.  The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Yousef,et al.  Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. , 2000, Clinical biochemistry.

[28]  O. Boerman,et al.  Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas. , 1991, The American journal of pathology.

[29]  P. Kruk,et al.  A simplified method to culture human ovarian surface epithelium. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[30]  S. Loening,et al.  Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. , 2002, Urology.

[31]  G. Mills,et al.  Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. , 2001, Journal of the National Cancer Institute.

[32]  P. Onyango.  Genomics and cancer , 2002, Current opinion in oncology.

[33]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[34]  D. Katsaros,et al.  Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. , 2003, Cancer research.

[35]  A. Scorilas,et al.  Human kallikrein 10: a novel tumor marker for ovarian carcinoma? , 2001, Clinica chimica acta; international journal of clinical chemistry.